W. Joseph Herring
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Sleep and related disorders, Sleep and Wakefulness Research, Circadian rhythm and melatonin, Anesthesia and Sedative Agents, Restless Legs Syndrome Research
Most-Cited Works
- → Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial(2014)505 cited
- → Orexin receptor antagonism for treatment of insomnia(2012)318 cited
- → Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials(2014)287 cited
- → A Randomized, Placebo-Controlled, Crossover Pilot Trial of the Oral Selective NR2B Antagonist MK-0657 in Patients With Treatment-Resistant Major Depressive Disorder(2012)213 cited
- → NMDA But Not Non-NMDA Excitotoxicity is Mediated by Poly(ADP-Ribose) Polymerase(2000)213 cited
- → Nuclear Targeting of Mutant Huntingtin Increases Toxicity(1999)192 cited
- → Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial(2020)181 cited
- → Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB family transcription factor-dependent mechanism(2000)177 cited
- → The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia(2016)123 cited
- → Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis(2014)118 cited